El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

Delgado et al_JHEP Rep_2025.pdf (2.37 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-03-03

Llicència de publicació

cc-by-nc-nd (c) Delgado, M. Eugenia et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222546

CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jhepr.2024.101296

Resum

Background & Aims Liver cancer is a significant global health issue, with its incidence rising in parallel with the obesity epidemic. The limited therapeutic options available emphasize the need for a better understanding of the molecular pathways involved in its pathogenesis. While much of the previous research has focused on transcriptional changes, this study examines translational alterations, specifically the role of cytoplasmic polyadenylation element binding protein 4 (CPEB4), a key regulator of translation. Methods We analyzed publicly available patient databases and conducted studies using human and mouse liver cancer cells, xenograft and allograft models, mouse models of high-fat diet-related liver cancer, and CPEB4 knockout and knockdown mice and cell lines. Results Patient data analysis (n = 87) showed a strong correlation between low CPEB4 levels and reduced survival rates (p <0.001). In mouse models of diet-induced liver cancer (n = 10–15 per group), both systemic and hepatocyte-specific CPEB4 knockout mice exhibited significantly increased tumor burden compared with wild-type controls (p <0.05). In vitro studies using human and murine liver cancer cells (n = 3 biological replicates) demonstrated reduced sensitivity to ferroptosis upon CPEB4 depletion when induced by erastin or RSL3 (p <0.01). Mechanistically, CPEB4 deficiency suppressed hepcidin expression, leading to elevated ferroportin levels, decreased intracellular iron accumulation, and reduced lipid peroxidation (p <0.05). Conclusions This study uncovers a novel CPEB4-dependent mechanism linking translational control to liver cancer progression and ferroptosis regulation. Therapeutic strategies targeting CPEB4-mediated pathways hold promise for advancing treatment options in liver cancer.

Matèries

Càncer de fetge, Marcadors tumorals

Matèries (anglès)

Liver cancer, Tumor markers

Citació

Col·leccions

Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

DELGADO, M. eugenia, NARANJO SUÁREZ, Salvador, RAMIREZ PEDRAZA, Marta, CÁRDENAS, Beatriz i., GALLARDO MARTÍNEZ, Carmen, BALVEY GIL, Alexandra, BELLOC ROCASALBAS, Eulàlia, MARTÍN ORTEGA, Judit, BOYLE, Mark, MÉNDEZ DE LA IGLESIA, Raúl, FERNÁNDEZ LOBATO, Mercedes. CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis. _Jhep Reports_. 2025. Vol. 7, núm. 3, pàgs. 101296. [consulta: 3 de gener de 2026]. ISSN: 2589-5559. [Disponible a: https://hdl.handle.net/2445/222546]

Exportar metadades

JSON - METS

Compartir registre